Skip to main content
. Author manuscript; available in PMC: 2021 Apr 16.
Published in final edited form as: J Thorac Oncol. 2018 Oct 10;14(2):237–244. doi: 10.1016/j.jtho.2018.10.003

Figure 2.

Figure 2.

Progression-free survival (PFS) by blinded independent central review with third- or later-line (3L+) nivolumab monotherapy. CI, confidence interval.

HHS Vulnerability Disclosure